Stockscreener 앱 받기
224.35
2.10%
-4.81
시간 외 거래:
224.35
전일 마감가:
$229.16
열려 있는:
$224.94
하루 거래량:
708.41K
Relative Volume:
0.81
시가총액:
$10.81B
수익:
$4.03B
순이익/손실:
$-182.84M
주가수익비율:
-59.66
EPS:
-3.7603
순현금흐름:
$391.29M
1주 성능:
-3.88%
1개월 성능:
+23.04%
6개월 성능:
+2.12%
1년 성능:
+43.17%
1일 변동 폭
$222.67
$228.53
1주일 범위
$222.67
$235.81
52주 변동 폭
$144.26
$237.86
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
224.35 | 11.04B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | 업그레이드 | CLSA | Hold → Outperform |
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now? - Yahoo Finance
How Charles River’s Expanded GMP NGS Role in ALA-101 Testing Will Impact Charles River (CRL) Investors - simplywall.st
Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued? - Yahoo Finance
Charles River Labs stock trades steady as recent earnings and guidance frame valuation - ad-hoc-news.de
Charles River Labs stock holds support as investors wait for fresh numbers. - Ad Hoc News
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Laboratories (CRL) to Report Q2 2026 Earnings on A - GuruFocus
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
Cell-Based Assay Services for Preclinical Use Only Global - GlobeNewswire
CRL5145816 Bond Risk Profile - TradingView
CRL5145816 Bond Coupon Profile — Rate & Payments - TradingView
Charles River Labs stock reflects steady demand for preclinical research services - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating - Moomoo
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside - TradingView
Charles River to Provide GMP NGS Services to Arovella - Contract Pharma
Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics - marketscreener.com
Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating - Moomoo
Charles River (CRL) Partners with Arovella Therapeutics for Canc - GuruFocus
Charles River partners with Arovella on cell therapy testing By Investing.com - Investing.com Australia
Charles River partners with Arovella on cell therapy testing - Investing.com
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches - Business Wire
Charles River Laboratories International (CRL) Expands AI Pathology Platform, Is The Valuation Upside Already Priced In? - simplywall.st
Charles River Laboratories stock hits 52-week high at $236.67 By Investing.com - Investing.com South Africa
Charles River Laboratories stock hits 52-week high at $236.67 - Investing.com
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories International Inc (CRL) Shares Surge 4.3% -- What GF Score of 69 Tells Investors - GuruFocus
Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 - Moomoo
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $226.79, Implies 1% Upside - TradingView
Charles River Laboratories highlights its role in drug development. Steady operations underpin the s - ad-hoc-news.de
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - TradingView
Charles River Labs explores growth opportunities as a research partner. Business model supports long - Ad Hoc News
Charles River (CRL) Analyst Initiates 90-Day Catalyst Watch - GuruFocus
Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree - Trefis
The Endotoxin Testing ServicesCharles River Labs leans on high-throughput biosafety work - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 - Moomoo
Charles River Labs business profile and stock context - Ad Hoc News
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026 - TradingView
Charles River Labs holds the line as investors await the next catalyst. - ad-hoc-news.de
Medpace Stock Outlook Turns on Backlog Quality and Cancellations - TradingView
CRLCharles River Laboratories International Inc Latest SEC Filings - Finviz
Are Analyst Upgrades Signaling a Turning Point in Charles River’s (CRL) Biopharma Pipeline Narrative? - simplywall.st
The In Vivo Pharmacology Services from Charles River LabsBehind a critical preclinical workhorse - ad-hoc-news.de
Charles River Labs tops estimates, shares gain on guidance - Investing.com
Charles River Shareholder Action Reminder - TMX Newsfile
Charles River Labs tops estimates, shares gain on guidance By Investing.com - Investing.com Nigeria
Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment? - Yahoo Finance
Charles River Labs stock holds steady on business context - AD HOC NEWS
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.61%
1.88%
자본화:
|
볼륨(24시간):